On October 17, 2022 Exacis Biotherapeutics Inc. ("Exacis" or the "Company"), a development-stage immuno-oncology company working to harness the immune system to cure cancer, reported that it has signed an option agreement with Eterna Therapeutics Inc. ("Eterna") providing Eterna the right to license up to four off-the-shelf, iPSC derived NK cell and T cell cancer treatments to be produced using Exacis’ proprietary mRNA-reprogrammed iPSCs that will be engineered with Exacis’ mRNA-based gene editing platform (Press release, Exacis Biotherapeutics, OCT 17, 2022, View Source [SID1234622083]). The option agreement provides Exacis and Eterna until December 31, 2022 to negotiate the license agreement. Terms include an upfront license fee, development and commercialization milestones, and single-digit royalties.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Exacis’ non-viral platform uses mRNA-reprogrammed iPSCs engineered for stealthing and performance using Exacis’ proprietary mRNA-based gene editing system including mRNA vector RiboSlice and nuclease NoveSlice. The Exacis process avoids use of potentially harmful DNA and viruses by using mRNA.
Dr. Dimitri Goundis, Exacis’ Chief Business Officer commented, "Exacis is committed to using its powerful platform to produce safe and effective immune cell therapies for cancer. Eterna is well positioned to rapidly advance products toward the clinic and patients".
Dr. Matt Angel, Eterna’s Interim Chief Executive Officer added, "The opportunity to partner with Exacis and add next-generation mRNA-based NK and T cell therapies to our oncology portfolio is an important step in advancing Eterna’s mission to realize the potential of cell engineering to provide patients with transformational new medicines."